SCHEMBL2012263

SCHEMBL2012263

CC(O)c1ccc2cccnc2c1-c1cccc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.56
CD74 P04233 1/20 0.44
MIF P14174 1/20 0.44
P4HB P07237 3/20 0.43
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
MDM2 Q00987 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MMP2 P08253 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011510 0.90 PIK3CD (0.45) PIK3CDCD74MIFP4HBMDM2
SCHEMBL2011258 0.87 PIK3CD (0.56) PIK3CDCD74MIFP4HBPDE4A
SCHEMBL2015805 0.85 PIK3CD (0.43) PIK3CDCD74MIFP4HBMDM2
SCHEMBL12632908 0.79 PIK3CD (0.44) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL2010635 0.76 PIK3CD (0.44) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL2011833 0.76 PIK3CD (0.45) PIK3CDCD74MIFP4HBMDM2
SCHEMBL2010930 0.76 TP53 (0.44) P4HBMDM2KDM4EGMNNLMNA
SCHEMBL2012265 0.74 PIK3CD (0.42) PIK3CDCD74MIFPDE4APDE4B
SCHEMBL2016212 0.74 PIK3CD (0.77) PIK3CD
SCHEMBL15139973 0.73 CCR1 (0.41) P4HBKDM4EGMNNLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 PIK3CD 13/4885CD74 391/4885MIF 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.